Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients

BACKGROUND: A new approach to the treatment of COPD includes controlling inflammation because of its important role in exacerbation of the disease. Recently, roflumilast has been added as a therapeutic option for COPD. Roflumilast is an oral phosphodiesterase-4 inhibitor that targets inflammatory ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Porpodis, Konstantinos, Domvri, Kalliopi, Zarogoulidis, Paul, Petridis, Dimitrios, Tsirgogianni, Katerina, Papaioannou, Antonis, Hatzizisi, Olga, Kioumis, Ioannis, Liaka, Alexandra, Kikidaki, Violeta, Lampaki, Sofia, Organtzis, John, Zarogoulidis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474389/
https://www.ncbi.nlm.nih.gov/pubmed/26109853
http://dx.doi.org/10.2147/COPD.S83205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474389/
https://www.ncbi.nlm.nih.gov/pubmed/26109853
http://dx.doi.org/10.2147/COPD.S83205

Ejemplares similares